News Search Results
Dec 27, 2024, 15:56 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
Jefferies downgraded Fortrea, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Fortrea's stock price fell $2.73 per share, or 12.29%, to close at $19.48
More news about: Pomerantz LLP
Dec 26, 2024, 20:29 ET Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with leading research
More news about: Ascentage Pharma
Dec 26, 2024, 18:11 ET AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B
/PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced
More news about: AusperBio Therapeutics Inc.
Dec 26, 2024, 11:26 ET Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
dose optimization data from Stage 1 of this Phase 3 trial in 2025." Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology company, recently
More news about: USA News Group
Dec 26, 2024, 09:31 ET Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that on December 19, 2024
More news about: Northwest Biotherapeutics
Dec 26, 2024, 09:30 ET Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Dec. 26, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that on December 19, 2024
More news about: Northwest Biotherapeutics
Dec 26, 2024, 08:34 ET Towards Better Hygiene Standards: Detecting Fecal Contamination of Water Using Viral DNA
medicine, sciences, and the arts, fostering innovation and global collaboration. Situated near Daedeok Innopolis, a major R&D hub, it excels in biotechnology, materials science, and information technology. With a vibrant international community and cutting-edge facilities, CNU continues to drive academic
More news about: Chungnam National University
Dec 26, 2024, 08:15 ET Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc.
More news about: Coeptis Therapeutics, Inc.